World’s First Minimally Invasive Non-blood Contacting Cardiac Device to Treat Acute Heart Failure.
With a lead investment from Wellcome Trust, CorInnova is developing a minimally invasive, non-blood contacting cardiac assist device for acute heart failure treatment. The device is intended to initially treat the large and fast-growing short-term cardiac assist market (up to 7 days’ use) and will expand this market up to 50% to a $6B addressable market by treating the 40% of patients who cannot use, or are unsuitable for, existing cardiac assist devices. The device is collapsible allowing it to be delivered and secured to the heart in a minimally invasive manner. The device conforms to the heart’s surface, and gently compresses the heart to increase cardiac output using an external pneumatic driver that operates in synchrony with the heartbeat.
The device increases cardiac output without touching the blood, thereby eliminating the risk of thrombosis and stroke due to device blood contact, the need for anti-coagulants, the risk of bleeding, and the risk of kidney dysfunction or damage.
News & Press Releases
Awards & Recognition
CorInnova wins “Most Promising Life Science Company” award from Rice Alliance for Technology and Entrepreneurship at Texas Life Science Forum
None of the statements or information contained on our website is an offer to buy or sell our securities. Offers to buy or sell our securities are made only pursuant to separate formal legal agreements. Nor should you make any investment decision based on the information on our website, but solely on that information contained in such legal agreements.